

Corporate & Investor Presentation

Updated: October 28, 2021

Presentation of financial information & forward-looking statements


Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities, for the periods indicated.

This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financial measures in this presentation, which include non-GAAP Income from Operations, non-GAAP Net Income, and non-GAAP Diluted Earnings per Share, should be considered in addition to, but not as substitutes for, the information prepared in accordance with GAAP. For reconciliations of the non-GAAP financial measures to the most comparable GAAP measures, please refer to the earnings release associated with the relevant reporting period, which can be found on the investor relations section of our corporate website (investor.resmed.com).

In addition to historical information, this presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on ResMed’s current expectations of future revenue or earnings, new product development, new product launches, new markets for its products, integration of acquisitions, leveraging of strategic investments, litigation, tax outlook, and the length and severity of the recent coronavirus outbreak, including its impacts across our business and operations. Forward-looking statements can generally be identified by terminology such as “may”, “will”, “should”, “expects”, “intends”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue”, or variations of these terms, or the negative of these terms or other comparable terminology.

ResMed’s expectations, beliefs, and forecasts are expressed in good faith and are believed to have a reasonable basis, but actual results could differ materially from those stated or implied by these forward-looking statements. ResMed assumes no obligation to update the forward-looking information in this presentation, whether as a result of new information, future events, or otherwise. For further discussion of the various factors that could impact actual events or results, please review the “Risk Factors” identified in ResMed’s quarterly and annual reports filed with the SEC. All forward-looking statements included in this presentation should be considered in the context of these risks. Investors and prospective investors are cautioned not to unduly rely on our forward-looking statements.

Company Overview & Strategy




Who we are / what we do

- Listed on NYSE & ASX, ~\$40B market cap
- World-leading digital health company with over 15.5 million 100% cloud-connectable devices
 - 17.5+ million patients in AirView monitoring ecosystem
 - 110+ million patient accounts in out-of-hospital care network
- Innovative designer and manufacturer of award-winning devices and cloud-based software solutions
 - Diagnose, treat, and manage sleep apnea, chronic obstructive pulmonary disease, and other respiratory conditions
- Products and solutions designed to improve patient quality of life, reduce impact of chronic disease, and lower healthcare costs
- Cloud-based software solutions and devices designed to provide connected care, improving patient outcomes and efficiencies for healthcare providers
 - Tools that allow fewer people to manage more patients
 - Empower patients to track own health outcomes



Why invest? – *driving long-term shareholder value*




Market Dynamics

- Underpenetrated markets in sleep and COPD
- Healthcare costs continue to increase
- Focus on improving patient outcomes
- Value-based technology solutions



Growth & Innovation

- Global leader in digital health for sleep and respiratory care
- Long-term growth opportunities
- 8,500+ patents and designs
- ~7-8% of revenue invested in R&D



Financial Results

- Historical revenue and profit growth
- Recurring revenue
- Operating excellence program
- Strong track record of disciplined capital deployment

Total Shareholder Return (NYSE shares as of 9/30/2021):

1-yr 55% ▪ 3-yr 136% ▪ 5-yr 334%

ResMed 2025 | Patient-centric, digitally-enabled strategy




250 million lives improved
in out-of-hospital healthcare
in 2025!

- Purpose** • Empower people to live happier, healthier, and **higher quality lives** in the comfort of their home

- Growth Focus** • Global health epidemics in **sleep apnea**, **COPD**, other major chronic conditions, and **SaaS** solutions that improve care in out-of-hospital settings


- Growth Advantage** • Transform care through **innovative solutions** and **tech-driven integrated care** to drive superior outcomes, experiences, and efficiency

- Growth Foundations** • High-performing, diverse, and entrepreneurial people
• Industry-leading innovation and business excellence
• Digital health technology and scientific leadership




Unlocking markets and expanding access with evidence and advocacy

Diverse evidence generating capabilities



Established scientific leader

of publications from 1996 onward



Better access and advocacy

Unlocking reimbursement

- U.S. Competitive Bidding Program delay and removal of NIV from the program
- Supporting the creation of new U.S. physician remote monitoring codes
- On-time device reimbursement in key markets

Thought leadership

- Achieved leadership positions in key global MedTech associations
- Thought leader in European and member state health data policy and remote monitoring reimbursement conversations

Engagement on key policies

- Health Technology Assessments (e.g., UK NICE)
- Analyses of French health insurance data to demonstrate the positive impact of CPAP therapy on lowering mortality rates

¹KOLs: Key opinion leaders

Strong history of market development and growth

Positioned to win

Growing the market

through commercial excellence and expanding market access


Driving digital innovation

in sleep and respiratory care to radically improve patient experience and outcomes

Transforming out-of-hospital care at scale

to drive better outcomes, lower costs, and improve quality of life

Our Business: Sleep & Respiratory Care



Proactive care to capture significant underpenetrated markets

Chronic disease is the largest driver of healthcare spending in developed economies

Sleep apnea

- **Leading indicator**, and a contributing factor, to many chronic illnesses
- More than **80% undiagnosed**
- Demonstrated positive dose-response relationship between **CPAP usage and lower healthcare costs**

COPD

- Largely undiagnosed COPD sufferers in high-growth markets such as China, India, Brazil, and E. Europe >100M²
- Acute treatment costs to healthcare systems are large
 - Europe: €48B per year⁴
 - U.S.: ~\$50B per year⁵
- More than 3M people worldwide die each year due to COPD¹

Asthma

- Significant opportunity to improve adherence and improve patient-physician interaction
- Leveraging Propeller for increased data related to symptom occurrence and acute triggers
- Opportunity to partner with patients, providers, pharmaceutical companies, and payors to drive improved quality of life

Total addressable market

936M sleep apnea patients

380M COPD patients^{2,3}

330M asthma patients⁶

Well-positioned to expand proactive treatment of chronic diseases

¹World Health Organization. The top 10 causes of death: Fact sheet: No310 (2014, May) accessed 20Jul16 ² <https://www.ncbi.nlm.nih.gov/pubmed/26755942> ³ Company estimates based on World Health Organization estimates and Zhong et al. "Prevalence of Chronic Obstructive Pulmonary Disease in China" *Respiratory and Critical Care* ⁴ European Respiratory Society, *European Lung White Book* <http://www.erswhitebook.org/chapters/the-economic-burden-of-lung-disease/> accessed 20Jul16 ⁵ Guarascio et al. Dove Med Press, 2013 Jun 17 ⁶ World Health Organization. Chronic obstructive pulmonary disease (COPD): Fact sheet No315. 2015 accessed 20Jul16

Driving digital innovation across Sleep and Respiratory Care

Well-positioned to drive digital innovation with...

Market-leading connected therapies and unique suite of software solutions


- Leveraging our device and software capabilities to increase patient engagement and success with therapy
- Driving greater provider efficiency and effectiveness to increase patient adherence and lower labor intensity
- Uniquely positioned to deliver value through our software solutions given access to rich and proprietary data from our connected devices



Building on our established leadership position to drive more **streamlined and integrated experiences** through **digitally powered integrated care models**

Leveraging our leadership position to transform Sleep and Respiratory Care

Transforming care by enabling an integrated healthcare model



Driving digital innovation across all aspects of the patient journey

Growing the market through new channels and partnerships

New channel



- Work closely with CVS to create streamlined sleep apnea patient journey in HealthHUB locations where patients can be screened, assessed, and setup on therapy as well as purchase related products all within the CVS ecosystem
- Educate CVS pharmacy colleagues, care concierge, and center of excellence team members; provide input into digital efforts to effectively identify presence of sleep apnea and provide recommendations for further testing as necessary

Joint venture



- Develop software solutions to identify, engage, and enroll individuals suffering from sleep apnea and other sleep-related disorders – *guide them to get diagnosed and successfully treated*
- Participate in the ecosystem of Verily companies to access sleep apnea patients and help them get diagnosed and treated
- Generate further evidence of the positive impact of sleep apnea treatment on other chronic health conditions

Expanding our ability to reach and serve patients

Leadership in OSA treatment with physical devices

Devices

Latest launch



AirSense™ 11



AirSense™ 10



AirCurve™ 10



AirMini™

Key differentiators

- Quietest, most intuitive devices on the market
- AirSense 11: newest, most connected device
 - Expanding digital tools for patient experience, including patient engagement built into device

Masks¹

Minimalist



AirFit™ F30

Freedom



AirFit™ F30i

Universal Fit



AirTouch™ F20

Ultra Soft



AirFit™ F20

- Premium comfort and machine-agnostic masks; widest range of masks on the market meeting the broadest set of patient needs

- Largest database of facial features; focused on designing for fit

- Expertise and experience in translating clinical knowledge into product features (e.g., comfort, durability)

Full Face



AirFit™ P10



AirFit™ N30



AirFit™ N30i



AirFit™ P30i



AirTouch™ N20



AirFit™ N20

Nasal

¹Current in-line masks being promoted; not an exhaustive list



Data-driven future of therapy


- AirSense 11 is a **two-way communication data platform**
 - **Both** cell and Bluetooth connectivity
 - **Seamless pairing with myAir app** and directly to the cloud
 - Very rich **consumer-like experience** on myAir app
 - Patient questions and prompts **on the device**
 - **Built for Over-the-Air (OTA) upgrades**
 - Add new features without new hardware
- **Improved patient adherence**
- **Even more streamlined provider workflows and lower costs**
- **Improved patient management**
 - Future: Patient Reported Outcomes Metrics (**PROMs**) for payors and health systems



AirSense™ 11

AirSense 11 is the device platform that will enable us to deploy AI/ML into sleep therapy

Leadership in OSA treatment with data applications



Key differentiators


- User-friendly, intuitive platform provides milestone accomplishments and motivation to patients, increasing therapy adherence, and improving sleep quality
- Focused on app enhancements to enable long-term adherence for life vs. short-term (e.g., app-based nudges)
- Clear-cut market leader with 4.0M U.S. patients registered to the myAir platform across the website and app
- Recently launched upgraded version: myAir 2.0

- Large installed base with over 17.5M patient enrolled in our cloud-based software solution
- Seamless integration with ResMed devices enhances provider efficiency and improves patient monitoring through industry-leading remote diagnostic tools
- Increased data capture enables us to drive more personalized care to improve the patient experience

Unlocking value for both patients and providers

At the forefront of Respiratory Care

Patient Management



AirView™ for Ventilation

Digital Therapeutics



Propeller

High-Flow Therapy



AcuCare™ HFNC
High flow nasal cannula



Lumis™
HFT

Bilevel Ventilation



AirCurve™ 10

Non-invasive Ventilation (NIV)



Lumis™ 100
VPAP ST

Stellar™ 100

Life Support Ventilation



Astral™



Astral™ 150
Life support ventilator

Patient Acuity

The right device, for the right patient, at the right time

Highlights

Widest range of therapies for higher acuity respiratory patients, including COPD and asthma

Broadest set of digitally connected respiratory therapy devices

Market leading platform for managing inhaled medications

Premier solution for remote management of ventilated patients

Leveraging our scale with data and digital solutions

With more than
10 billion nights of
therapy
usage data we
have a unique
ability to create
actionable insights:

Now

For Patients

- Coaching and usage help in context through myAir app

For Providers

- Patient management by exception, streamlined workflows, lower costs, higher adherence, and increased revenue

For Payors

- Increased patient adherence and improved ROI on therapy

Next

For Patients

- **Personalized** coaching in myAir based on ML

For Providers

- Patient management by *prediction*

For Payors

- **Proof** that it pays to find and treat sleep apnea patients; improved patient management with PROMs


Benefitting all stakeholders with better outcomes and lower costs

Our Business: Software as a Service (SaaS)




Leading provider of cloud-based software for out-of-hospital care providers across multiple settings

Our breadth uniquely positions us to be the innovation engine for providers



We are the gateway to out-of-hospital care

We have a leading position across these markets




One of the leading market positions across the markets we serve – with room to grow

Uniquely positioned to address provider needs




Demand for greater coordination across provider markets




- Providers are diversifying and lines are blurring across the continuum; Skilled nursing facility owners are moving into home-based care
- We are working with our customers to address their needs, holistically across the markets they serve
- Our solutions are supported by the richness of our data

Differentiated value creation within SaaS portfolio through breadth and commitment to innovation

Digital Health Technology




Our digital health solutions improve outcomes and lower costs



Focused on interoperability so our ecosystem works with the broader healthcare ecosystem

We transform 10+ billion nights of medical data into useful outcomes

End-to-end digital health solutions in sleep, respiratory care, and out-of-hospital healthcare



Global leader in digital health

**AirView™ has
17.5+ million patients**

1.5+ million diagnostic tests
processed **in the cloud**


~100 API calls per
second from integrators

>15.5 million
100% cloud connectable
devices worldwide

>110 million accounts in
out-of-hospital care network

4+ million patients have
signed up for **myAir™**

Recent Quarterly Results




Q1 FY22 financial results

| \$ in millions, except per share amounts | | 1Q22 |
|--|---------|---------------|
| Revenue | \$904.0 | +20%, +19% CC |
| Non-GAAP gross margin* | 57.2% | (270) bps |
| Non-GAAP operating income* | \$280.7 | +18% |
| Non-GAAP EPS* | \$1.51 | +19% |

* Refer to Non-GAAP reconciliations in the Appendix.

*Diversified revenue
by business & by geography*



Capital allocation

| \$ in millions | 1Q22 |
|----------------------------------|--------------------|
| Cash and cash equivalents | \$276 |
| Debt | \$806 |
| Net debt | \$530 |
| Non-GAAP free cash flow | \$192 ¹ |
| Unused borrowing capacity | \$1,450 |

NOTE: Values may not calculate due to rounding

¹Adjusted for one-time ATO settlement payment of \$284.8M in Sep/21

| During 1Q22 |
|--|
| \$60M invested in R&D (7% of revenue) |
| Paid \$61M in dividends to shareholders |

Higher priority
↑

Reinvest for growth

- Reinvest in product development for high-return organic growth
- 7% of FY 2021 revenue invested in R&D

Pursue M&A

- Actively evaluate potential acquisitions
- Pursue targets aligned with long-term strategic goals and financial objectives

Support dividends


- Regular return of cash to shareholders through dividend at a level that is meaningful and sustained

↓ Lower priority

Opportunistically repurchase shares

- Opportunistic repurchase of shares
- Current program suspended following acquisitions of MatrixCare and Propeller

Track record of strong financial returns for shareholders




Total shareholder return, TSR (NYSE shares as of 9/30/2021): 1-yr 55% | 3-yr 136% | 5-yr 334%

NOTE: See reconciliation to GAAP in Appendix

Our **vision** is to empower people to take control of their health so they can sleep better, breathe better, and live better lives outside the hospital



*In the last 12 months, we changed over **130 million lives** with our digital health products and cloud-based software solutions*



*Our aspiration is to improve
250 million lives in 2025*


Contact Investor Relations

Phone: (858) 836-5971

Email: investorrelations@resmed.com

Website: investor.resmed.com

APPENDIX



ResMed

Reconciliation of non-GAAP financial measures

The measures “non-GAAP gross profit” and “non-GAAP gross margin” excludes amortization expense from acquired intangibles related to cost of sales and are reconciled below:

(Unaudited; \$ in thousands, except for per share amounts)

| | Three Months Ended | |
|---|-----------------------|-----------------------|
| | September 30, 2021 | September 30, 2020 |
| Revenue | \$ 904,015 | \$ 751,944 |
| GAAP cost of sales | \$ 397,726 | \$ 313,283 |
| Less: Amortization of acquired intangibles ^(A) | (11,059) | (11,979) |
| Non-GAAP cost of sales | \$ 386,667 | \$ 301,304 |
| GAAP gross profit | \$ 506,289 | \$ 438,661 |
| GAAP gross margin | 56.0 % | 58.3 % |
| Non-GAAP gross profit | \$ 517,348 | \$ 450,640 |
| Non-GAAP gross margin | 57.2 % | 59.9 % |

(A) ResMed adjusts for the impact of the amortization of acquired intangibles, reserve for disputed tax positions and the (gain) loss on equity investments from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.

ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed's performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.

Reconciliation of non-GAAP financial measures, cont'd

The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below:

(Unaudited; \$ in thousands, except for per share amounts)

| | Three Months Ended | |
|--|-----------------------|-----------------------|
| | September 30, 2021 | September 30, 2020 |
| GAAP income from operations | \$ 261,913 | \$ 216,896 |
| Amortization of acquired intangibles - cost of sales ^(A) | 11,059 | 11,979 |
| Amortization of acquired intangibles - operating expenses ^(A) | 7,707 | 8,243 |
| Non-GAAP income from operations | <u>\$ 280,679</u> | <u>\$ 237,118</u> |

(A) ResMed adjusts for the impact of the amortization of acquired intangibles, reserve for disputed tax positions and the (gain) loss on equity investments from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.

ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed's performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.

Reconciliation of non-GAAP financial measures, cont'd

The measure "non-GAAP net income" and "non-GAAP diluted earnings per share" are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:

(Unaudited; \$ in thousands, except for per share amounts)

| | Three Months Ended | |
|--|-----------------------|-----------------------|
| | September 30, 2021 | September 30, 2020 |
| GAAP net income | \$ 203,613 | \$ 178,372 |
| Amortization of acquired intangibles - cost of sales, net of tax ^(A) | 8,435 | 9,169 |
| Amortization of acquired intangibles - operating expenses, net of tax ^(A) | 5,878 | 6,309 |
| Reserve for disputed tax position ^(A) | 4,111 | - |
| (Gain) loss on equity investments ^(A) | - | (8,476) |
| Non-GAAP net income ^(A) | <u>\$ 222,037</u> | <u>\$ 185,374</u> |
| GAAP diluted shares outstanding | 146,860 | 146,100 |
| GAAP diluted earnings per share | \$ 1.39 | \$ 1.22 |
| Non-GAAP diluted earnings per share ^(A) | \$ 1.51 | \$ 1.27 |

(A) ResMed adjusts for the impact of the amortization of acquired intangibles, reserve for disputed tax positions and the (gain) loss on equity investments from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.

ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed's performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.

Our response to COVID-19: Focused on preservation of life

Our ResMed Team

- Work-from-home policy for all employees when job can be performed remotely
- Specific actions to protect and support employees working in our manufacturing and distribution sites, including:
 - split shifts (A/B/C)
 - increased cleaning, personal hygiene, and safety protocols including temperature checks
 - personal protective equipment for all staff (PPE)
- Increased cadence of communications and engagement with employees

Our Stakeholders

- Fair and ethical allocation of products globally supported by an epidemiological model
- Transitioned manufacturing lines to support production of ventilation products to meet global demand
 - Tripled manufacturing of ventilators
 - Scaled up ventilation mask production more than 10x
- Updated and ongoing clinical information
- Increased digital health technology and remote patient care services for customers

Business Continuity

- Established key workstreams and a central task force to guide and manage ResMed through the crisis
- Ongoing communication with suppliers and partners to ensure continuity and identify gaps
- Active engagement with key government officials and healthcare systems worldwide
- Ongoing business modeling and scenario planning
- Prudent cash and expense management

Striving for excellence in environmental, social, and governance processes

| Eliminating unnecessary waste | Minimizing pollution | Product stewardship | Responsible compliance | Increased awareness and continual improvement |
|--|--|---|---|--|
| We work to eliminate unnecessary waste in all our systems & processes, such as minimizing our use of natural resources. | We are minimizing pollution, in particular our non-biodegradable waste to landfill. | We design and develop products with reduced impact on the environment through their lifecycle. | We fulfill all relevant and applicable compliance obligations in the countries and communities that we operate in. | We drive internal awareness of environmental impacts and monitor our performance through collaboration with others to make continual improvements |



Recognized by others for leading in this space:

- #106 on Newsweek's 2021 "America's Most Responsible Companies", #15 in Healthcare & Life Sciences
- #105 on WSJ's 2020 "Management Top 250", #18 in Healthcare / Life Sciences



Turning big data into actionable information

Pioneering *innovation* and providing *clinical evidence* that support better patient outcomes and improved business efficiencies for customers



AirView™



Labor
Costs²



New
Patient
Setups³



myAir™



World's largest study for adherence

> 128,000 patients



1. Hwang, et al., AJRCCM 2017

2. Munafò, et al. Sleep Breath 2016


3. Data based on monthly patient setups and compliance rates of DME customers from February 2014 – March 2015. Historical results for this provider over the stated time

4. Malhotra et al CHEST 2018

Improving adherence to therapy with patient monitoring and resupply

ResAdhere: remote monitoring + mask resupply drive improved adherence

In a study of ~100k patients with AirView cloud-connected devices...



...the likelihood of therapy termination decreased by >50% after one year
and there was a significant increase in daily PAP usage

Benjafield, et al. AJRCCM 2018 (abstract)

Note: De-identified data from Brightree and AirView were sent to a third-party independent statistician who provided the anonymized analyses and findings.

Long-term CPAP treatment decreases mortality rates and reduces the risk of comorbidities

Recent prospective cohort study from the UK published in ERJ Open Research reconfirms treating OSA with CPAP improves health outcomes

30

year study duration

4,502

diagnosed OSA patients

15

year average follow-up time

Those who did not use CPAP were **5.63x** more likely to die than a long-term (>5 years) CPAP user

The study also reconfirms with new data that untreated OSA leads to a greater risk in developing:



Myocardial Infarction (heart attack)



Type 2 Diabetes Mellitus




Ischemic Heart Disease

Reducing mortality with PAP therapy

U.S. multicenter, population-based cohort study




- Study included 392 patients with sleep apnea, with 11 years of follow-up
- Positive airway pressure therapy associated with a **62% lower risk of all-cause mortality**
- Death rate was twice as high for persons who did not receive positive airway pressure therapy
 - (24.7 vs 12.8 deaths per 1000 person years, $p = 0.03$)



Demonstrated positive dose-response relationship between increased CPAP usage and lower healthcare costs

For every **one hour per night** increase in PAP usage there was an **8% decrease** in inpatient visits and a **4% decrease** in overall acute care visits.¹



1. Kirsch DB et al. *J Clin Sleep Med* 2019

* Overall visits" includes inpatient, ED, and observation visits.


Study demonstrates the effectiveness of CPAP therapy and quality of life improvements for those with mild obstructive sleep apnea

MERGE trial: clinical effectiveness of CPAP treatment in patients with mild obstructive sleep apnea


- Demonstrated improvement in Quality of Life (SF-36 vitality scale) for CPAP patients vs. standard care
- Symptomatic benefits:
 - Reductions in sleepiness
 - Improvements in fatigue and depression

Compelling evidence supports the need and benefits of treating mild OSA

Combined with recently published global prevalence research, 936M patients worldwide can benefit from PAP treatment




Change in SF-36 Vitality Scale
in Patients with Mild OSA per AASM 2012



Big data analysis drives insights for treatment of central sleep apnea

Patients with treatment-emergent central sleep apnea (CSA) are 2x more likely to terminate therapy

- Opportunity to rethink conventional therapeutic options
- Minimize risk of therapy termination through early diagnosis
- Regularly monitor patients to support adherence to treatment




- Switching from therapy CPAP to ASV improved relative adherence by 22%
- Patients who switched from CPAP to ASV had fewer apneas and hyponeas during sleep

Opportunity to shift care from hospital to home

- Healthcare costs are on the rise
- Combining non-invasive ventilation (NIV) with home oxygen therapy (HOT)
 - Reduces hospitalization and mortality by 51%
 - Increases time to hospital readmission or death by ~90 days

JAMA®
The Journal of the American Medical Association




- Combination of HOT with NIV reduced hospital readmissions by 58.3%
- Combination of therapies provided improved patient quality of life and saved >\$50k per quality of life adjusted year

1 P. Murphy et al., Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation. A Randomized Clinical Trial, JAMA .Published online May 21, 2017. doi:10.1001/jama.2017.4451.

Digital health solutions for inhaled COPD pharmaceuticals


- ResMed has end-to-end digital health solutions for COPD patients across stages I, II, III, IV of the disease
- Uses sensors with inhalers to track medication usage and provide personal feedback and insights
- Establishes ResMed as a leading provider of COPD and asthma patient management solutions
- Enables digital integration of care through the progression of the disease



Propeller has demonstrated compelling clinical outcomes




Impact of the Propeller solution tracking inhaler usage and location



Uncontrolled
COPD


SABA use over time

per day





Symptom free days

%



Healthcare utilization


Events



Uncontrolled
Asthma


Adherence

%




QoL: Rescue Inhaler use per day

times used



Acute care utilization

Events per 100 patient years



Propeller's digital medicine platform drives reduced healthcare utilization




Study Overview:

Cleveland Clinic enrolled people into Propeller as part of their routine clinical care and monitored them for at least one year. Providers monitored drug use and adherence to inhaled controller medications, providing follow-up as needed.

Population:

- COPD patients with ≥ 1 utilization (Emergency Department ("ED") visit or hospitalization) in prior 12 months
- N = 39; mean age: 69 years, 51% male, 69% African American, mean FEV₁¹ predicted: 47.2%, mean CAT: 19²

Results:



1. FEV₁ = Forced Expiratory Volume in 1 second – the volume of air that can be forcibly blown out in the first second after full inspiration. Values between 80% and 120% are considered normal

2. CAT = COPD Assessment Test – an eight-item questionnaire designed to quantify the impact of COPD symptoms on a patient's health status.. Scored between 0-40, <10 Low, 10-20 Medium, 21-30 High, >30 Very high

Alshabani K, et al. Electronic inhaler monitoring and healthcare utilization in chronic obstructive pulmonary disease. J Telemed Telecare. 2019

Strong track record of M&A

Our transformative acquisitions have enabled tuck-in opportunities, creating added capabilities



+



+



Added Capabilities



2017

Enhanced HMEs' custom forms and workflow solutions



2017

Provided live call center services for HMEs



2018

Added mobile applications to empower companies to automate and streamline business processes



2018

Software solutions to optimize clinical, financial, and administrative processes




2020

Elevated Brightree's ReSupply platform, creating the largest CPAP resupply patient base



2021

Enhanced real-time communication technology, specifically real-time response, to inbound communications



ResMed

Enhanced portfolio

Proven ability to integrate and leverage transformative acquisitions and tuck-ins